OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy.

OBJECTIVES: OSKIRA-4 evaluated the efficacy of fostamatinib monotherapy versus placebo on the signs and symptoms of rheumatoid arthritis over 6 weeks by Disease Activity Score C reactive protein (DAS-28(CRP)) and assessed non-inferiority to adalimumab monotherapy at Week 24 by DAS-28(CRP). METHODS:...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính: Taylor, P, Genovese, M, Greenwood, M, Ho, M, Nasonov, E, Oemar, B, Stoilov, R, Vencovsky, J, Weinblatt, M
Định dạng: Journal article
Ngôn ngữ:English
Được phát hành: 2014